Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Janux Therapeutics
Study ID
NCT07545811
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JANX014 — BIOLOGICAL
    JANX014 will be administered via IV dosing

Study Details

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Key Dates

First listed
Apr 22, 2026
Start date
Apr 15, 2026
Status verified
Aug 2026
Primary completion
May 31, 2028
Completion
Mar 31, 2029

Study Design

Enrollment
43 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation
    JANX014 will be administered at increasing dose levels per cohort to determine the maximum tolerated dose.
  • Experimental: Dose Expansion
    Participants will be dosed at levels previously declared tolerable.

Primary Outcome Measure

Incidence of Dose Limiting Toxicities (DLTs) [ Time Frame: 2 years ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63108-
Prisma Health Cancer InstituteGreenvilleSouth Carolina29605-
SCRI Oncology PartnersNashvilleTennessee37203-
SCRI at Mary CrowleyDallasTexas75230-

Find similar trials in St Louis, MO

Nationwide
Prostate cancer trialsOncology trialsProstate oncology trialsMen's health trialsUrology trials
By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Washington University School of Medicine· St Louis, MOPrisma Health Cancer Institute· Greenville, SCSCRI Oncology Partners· Nashville, TNSCRI at Mary Crowley· Dallas, TX

Related Studies